Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based
Analysis of 426 Patients

J 2018

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ et. al.

Základní údaje

Originální název

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Autoři

POPRACH, Alexandr (203 Česká republika, garant, domácí), Ondrej FIALA (203 Česká republika), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Bohuslav MELICHAR (203 Česká republika), Radek LAKOMÝ (203 Česká republika, domácí), Katarína PETRÁKOVÁ (203 Česká republika, domácí), Milada ZEMANOVA (203 Česká republika), Katerina KOPECKOVA (203 Česká republika), Ondřej SLABÝ (203 Česká republika, domácí), Hana STUDENTOVA (203 Česká republika), Jindrich KOPECKY (203 Česká republika), Igor KISS (203 Česká republika, domácí), Jindrich FINEK (203 Česká republika), Ladislav DUŠEK (203 Česká republika) a Tomas BUCHLER (203 Česká republika)

Vydání

Anticancer Research, Athens, The International Institute of Anticancer Research, 2018, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.935

Kód RIV

RIV/00216224:14110/18:00102719

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/anticanres.12243

UT WoS

000419130100060

Klíčová slova anglicky

Renal cell carcinoma; pazopanib; response; survival; cancer registry

Štítky

14110811, 14119612, EL OK, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 4. 2021 13:46, Mgr. Tereza Miškechová

Anotace

V originále

Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

NT13547, projekt VaV

Název: Studium mikroRNA a genů asociovaných s procesem epiteliálně-mezenchymální tranzice jako potenciálních markerů pro predikci rizika a časný záchyt metastazování u pacientů s renálním karcinomem

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

90004, velká výzkumná infrastruktura

Název: BBMRI-CZ

Citovat

POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ, Katarína PETRÁKOVÁ, Milada ZEMANOVA, Katerina KOPECKOVA, Ondřej SLABÝ, Hana STUDENTOVA, Jindrich KOPECKY, Igor KISS, Jindrich FINEK, Ladislav DUŠEK a Tomas BUCHLER. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. Anticancer Research. Athens: The International Institute of Anticancer Research, 2018, roč. 38, č. 1, s. 449-456. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.12243.

@article{1417179,
   author = {Poprach, Alexandr and Fiala, Ondrej and Chloupková, Renata and Melichar, Bohuslav and Lakomý, Radek and Petráková, Katarína and Zemanova, Milada and Kopeckova, Katerina and Slabý, Ondřej and Studentova, Hana and Kopecky, Jindrich and Kiss, Igor and Finek, Jindrich and Dušek, Ladislav and Buchler, Tomas},
   article_location = {Athens},
   article_number = {1},
   doi = {http://dx.doi.org/10.21873/anticanres.12243},
   keywords = {Renal cell carcinoma; pazopanib; response; survival; cancer registry},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients},
   url = {https://ar.iiarjournals.org/content/38/1/449.long},
   volume = {38},
   year = {2018}
}

TY  - JOUR
ID  - 1417179
AU  - Poprach, Alexandr - Fiala, Ondrej - Chloupková, Renata - Melichar, Bohuslav - Lakomý, Radek - Petráková, Katarína - Zemanova, Milada - Kopeckova, Katerina - Slabý, Ondřej - Studentova, Hana - Kopecky, Jindrich - Kiss, Igor - Finek, Jindrich - Dušek, Ladislav - Buchler, Tomas
PY  - 2018
TI  - Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
JF  - Anticancer Research
VL  - 38
IS  - 1
SP  - 449-456
EP  - 449-456
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Renal cell carcinoma
KW  - pazopanib
KW  - response
KW  - survival
KW  - cancer registry
UR  - https://ar.iiarjournals.org/content/38/1/449.long
N2  - Background: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. Patients and Methods: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. Results: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. Conclusion: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
ER  -

POPRACH, Alexandr, Ondrej FIALA, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Radek LAKOMÝ, Katarína PETRÁKOVÁ, Milada ZEMANOVA, Katerina KOPECKOVA, Ondřej SLABÝ, Hana STUDENTOVA, Jindrich KOPECKY, Igor KISS, Jindrich FINEK, Ladislav DUŠEK a Tomas BUCHLER. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2018, roč.~38, č.~1, s.~449-456. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.12243.

Podrobný výpis o publikaci